VCY1B activity is tightly regulated by intracellular cyclic adenosine monophosphate (cAMP) levels. Compounds that enhance adenylyl cyclase activity or prevent the degradation of cAMP can therefore indirectly contribute to the activation of VCY1B. For instance, agents that directly stimulate adenylyl cyclase result in a surge of cAMP production. This second messenger plays a pivotal role in various signaling pathways and can lead to an increase in VCY1B activity. Similarly, certain molecules that bind to G protein-coupled receptors initiate a signaling cascade that culminates in the activation of adenylyl cyclase, further bolstering cAMP levels. These elevated levels of cAMP, in turn, can have a downstream effect on VCY1B, enhancing its activity within the cell. Additionally, the activity of VCY1B is influenced by compounds that inhibit the breakdown of cAMP, thereby sustaining its presence and action within the cellular environment. By preventing the degradation of cAMP, these inhibitors ensure that the second messenger remains available to propagate signaling required for VCY1B activation.
On the other hand, the modulation of VCY1B activity is also subject to regulation by ions that serve as cofactors for enzymes involved in cAMP synthesis. These ions can positively influence the catalytic efficiency of adenylyl cyclase, thereby increasing cAMP production and indirectly promoting VCY1B activity. Moreover, the pharmacological inhibition of specific phosphodiesterase enzymes leads to an accumulation of cAMP by halting its hydrolysis. This rise in cAMP levels can be conducive to the functional activation of VCY1B. In summary, the dynamic interplay of various compounds that either boost the synthesis or impede the degradation of cAMP converges to modulate the activity of VCY1B, positioning it as a key node in the network of cellular signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Directly stimulates adenylyl cyclase, increasing cAMP levels, which can enhance VCY1B activity. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
β-adrenergic agonist that elevates cAMP by activating adenylyl cyclase, indirectly activating VCY1B. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Non-specific phosphodiesterase inhibitor that prevents cAMP degradation, supporting VCY1B activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Selective phosphodiesterase-4 inhibitor, raising cAMP levels and potentially activating VCY1B. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $56.00 $156.00 $270.00 $665.00 | 37 | |
Activates adenylate cyclase via prostaglandin E2 receptors, increasing cAMP, potentially activating VCY1B. | ||||||
Manganese(II) chloride beads | 7773-01-5 | sc-252989 sc-252989A | 100 g 500 g | $19.00 $30.00 | ||
Manganese ions can act as cofactors for adenylyl cyclase, enhancing its activity and thereby increasing cAMP levels, which may activate VCY1B. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Stimulates adenylyl cyclase through β-adrenergic receptors, increasing cAMP and potentially activating VCY1B. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Binds to dopamine receptors that can stimulate adenylyl cyclase, possibly leading to VCY1B activation. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $147.00 | ||
Inhibits phosphodiesterase III, increasing cAMP levels which may result in VCY1B activation. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Selective phosphodiesterase-3 inhibitor that increases intracellular cAMP, potentially activating VCY1B. | ||||||